Trial Outcomes & Findings for Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation (NCT NCT02417870)

Last Updated: 2021-06-24

Results Overview

Recruitment status

TERMINATED

Study phase

PHASE1/PHASE2

Target enrollment

2 participants

Primary outcome timeframe

6 weeks

Results posted on

2021-06-24

Withdrawal data not reported

Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation

Baseline characteristics by cohort
Measure	Aldesleukin n=2 Participants aldesleukin
Age, Categorical <=18 years	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	1 Participants n=5 Participants
Age, Categorical >=65 years	1 Participants n=5 Participants
Sex: Female, Male Female	0 Participants n=5 Participants
Sex: Female, Male Male	2 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants
Race (NIH/OMB) White	2 Participants n=5 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants
Region of Enrollment United States	2 participants n=5 Participants

Timeframe: 6 weeks

Population: Study was termination prior to completion

Outcome data not reported

Serious events: 1 serious events

Other events: 2 other events

Deaths: 0 deaths

Serious adverse events
Measure	Aldesleukin n=2 participants at risk aldesleukin
Cardiac disorders ischemic heart disease	50.0% 1/2 • Number of events 1 • 6 weeks

Other adverse events
Measure	Aldesleukin n=2 participants at risk aldesleukin
General disorders Elevated Creatinine	100.0% 2/2 • 6 weeks

Brigham and Women's Hospital

Phone: 617-732-7412